- Home
- NERV vs PALI Comparison
NERV vs PALI Comparison
Compare NERV & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NERV | PALI |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.6M | 333.6M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NERV | PALI |
|---|---|---|
| Price | $5.31 | $2.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $10.50 | ★ $11.29 |
| AVG Volume (30 Days) | 129.8K | ★ 3.2M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,175,600.00 | $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $1.35 | $0.55 |
| 52 Week High | $12.46 | $2.86 |
Technical Indicators
Market Signals| Indicator | NERV | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 50.98 |
| Support Level | $5.02 | $1.57 |
| Resistance Level | $6.69 | $2.18 |
| Average True Range (ATR) | 0.42 | 0.13 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 46.96 | 48.35 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.